Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 14, Issue 36, Pages 3780-3789Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161208786898635
Keywords
Angiogenesis; vasculogenesis; endothelial cells; endothelial progenitors; tumor; cancer
Categories
Funding
- AIRC (Associazione Italiana per la Ricerca sul Cancro)
- ISS (Istituto Superiore di Sanita)
- Ministero della Gainte [RF-IMI-2006-411189]
- Sixth EU Framework Programme [504743]
Ask authors/readers for more resources
Circulating endothelial cell (CEC) and progenitor (CEP) number and viability are modulated in various pathological conditions including cancer. There is increasing evidence showing that CEC and CEP play a role in cancer progression and metastasis in different animal models. At the clinical level, emerging data support that CEC and CEP kinetics and viability might predict the efficacy on anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, CEC and CEP measurements have attractive potential diagnostic and therapeutic applications for malignant diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
